Osteoporosis Drug Reduces Spinal Damage in Zebrafish Study
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Edinburgh and Bristol researchers bred zebrafish without a functioning collagen IX-related gene and found altered gene activity caused minerals to accumulate in spinal discs — resembling bone forming where it shouldn't — driving intervertebral disc degeneration (IVDD), for which no medication currently exists.
- The zebrafish developed human-like disc disease as they aged: vertebrae fused and mineral deposits hardened tissue between bones, but only after a supportive scaffold layer within the spine first deteriorated.
- A bisphosphonate, a bone-protecting osteoporosis drug already in clinical use, prevented mineral buildup and reduced spinal fusion; reduced food intake and drugs suppressing fat metabolism also cut fusion in the fish.
- Gene activity analysis linked the mineralization to disrupted fat processing, the mTOR growth-regulating pathway, phosphate control, and vitamin A signaling — all associated with abnormal mineral accumulation.
- Dr. Erika Kague, who led the study at Edinburgh's Institute of Genetics and Cancer, said surgery has been "the only real answer for disc disease" for decades and called the findings "super exciting."
- Arthritis UK — which noted the research affects 9.5 million people in the UK living with back pain — and the BBSRC funded the study, published in the journal Communications Biology.
Why it matters: For the 9.5 million UK residents with back pain and millions more worldwide, the finding that a bisphosphonate already approved for osteoporosis reduced mineral buildup in zebrafish provides the first drug-based evidence against intervertebral disc degeneration, where surgery remains the sole long-term option.
